

## **Airsonett® AIR4 can generate significant cost savings while still maintaining asthma-related quality of life according to an independent expert review**

An independent expert review authored by John O Warner, Professor of Paediatrics, Imperial College London, was today published on-line in *Therapeutic Advances in Respiratory Disease*. The review concludes that temperature-controlled laminar airflow (TLA) treatment (Airsonett AIR4) improves asthma-related quality of life, reduces airway inflammation and the frequency of severe asthma exacerbations in patients with severe allergic asthma. As these patients might otherwise be considered for treatment with expensive biologicals, Prof Warner suggest that employment of Airsonett AIR4 in this patient population could generate significant cost savings while still maintaining quality of life.

Prof Warner has an extensive knowledge of paediatric allergic diseases and a vast experience of using the Airsonett device both in a clinical and research setting. He was a key member of the scientific advisory board designing and over-seeing the conduct of the pivotal 12-month trial<sup>1</sup> and he also lead the scientific team that conducted the health economic analysis recently published<sup>2</sup>.

In addition to the comprehensive review of the scientific evidence supporting the efficacy of Airsonett AIR4, Prof Warner also highlights that patients and families are welcoming recommendations on relevant allergen avoidance strategies and that 'families were very keen to be enrolled' in the Airsonett study he conducted.

- *As a non-invasive, home based, drug free treatment, Airsonett AIR4 is an attractive therapy for allergic asthma patients. We welcome this independent expert review by Professor John O Warner reinforcing the value that we believe Airsonett AIR4 can bring to patients, their families and the health care system, says Fredrik Werner, CEO, Airsonett AB.*

**Citation:** Warner JO. Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience. *Ther Adv Respir Dis* (2017). Pre-published online as [DOI: 10.1177/1753465817690505](https://doi.org/10.1177/1753465817690505)

### **FOR MORE INFORMATION, PLEASE CONTACT:**

Fredrik Werner, CEO, Airsonett AB  
Tel: +46 708 494 862  
E-mail: [fredrik.werner@airsonett.eu](mailto:fredrik.werner@airsonett.eu)

### **FOR ACCESS TO HIGH-RESOLUTION PICTURES, PLEASE CONTACT:**

Annica Anderberg  
Tel: +44 7787 123 556  
E-mail: [annica.anderberg@airsonett.eu](mailto:annica.anderberg@airsonett.eu)

### **About Airsonett**

Airsonett AIR4 is a drug-free home based treatment option for patients with persistent allergic asthma who remain poorly controlled despite treatment with conventional pharmacological therapy. Airsonett uses the unique, patented Temperature controlled Laminar Airflow technology to significantly reduce allergens and other airborne irritants from the patient's breathing zone during night.<sup>3</sup> Airsonett AIR4 is a CE marked class 1 intended to be used for the alleviation of symptoms of allergy induced diseases such as allergic asthma. It adheres to relevant EU directives regarding design, function, safety and health

requirements and has undergone rigorous clinical research as well as health economy studies. Airsonett AB is a Swedish-owned company. The main share owners are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit [www.airsonett.com](http://www.airsonett.com)

**Scientific references:**

1. Boyle RJ, Pedroletti C, Wickman M, et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. *Thorax* 2012;67:215-221
2. Brazier P, Schauer U, Hamelmann E, Holmes S, Pritchard C and Warner JO. Economic analysis of temperature-controlled laminar airflow (TLA) for the treatment of patients with severe persistent allergic asthma. *BMJ Open Resp Res* 2016;3:e000117 doi:10.1136/bmjresp-2015-000117
3. Gore RB, Boyle RJ, Gore C, et al. Effect of a novel temperature-controlled laminar airflow device on personal breathing zone aeroallergen exposure. *Indoor Air* 2015;25:3644